Metis TechBio and Eli Lilly strike drug delivery collaboration worth up to $1.1 billion

On October 19, 2026, Hong Kong-listed Metis TechBio entered into a drug delivery collaboration with Eli Lilly worth up to $1.1 billion. Metis TechBio will receive a low double-digit million-dollar upfront payment, potential milestone payments reaching $1.1 billion, and tiered single-digit royalties. Metis TechBio will deploy its proprietary AI-driven ionizable lipid discovery platform to design novel LNP architectures, aiming to improve tissue specificity, biodistribution, and therapeutic performance across multiple disease areas.

Financial terms of the agreement

• ▪On October 19, 2026, Hong Kong-listed biotech Metis TechBio announced a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop drug delivery technologies.
• ▪Metis TechBio is eligible to earn up to about $1.1 billion in development, regulatory, and commercial milestone payments from Eli Lilly, plus tiered single-digit percentage royalties on annual net sales.
• ▪Under the collaboration agreement, Metis TechBio is eligible to receive an upfront payment from Eli Lilly in the low double-digit millions of U.S. dollars.

Development of novel lipid nanoparticle architectures

• ▪Metis TechBio will utilize its proprietary AI-driven ionizable lipid discovery and optimization platform to improve the targeting and biodistribution of lipid nanoparticle therapies under the Eli Lilly agreement.
• ▪The novel lipid nanoparticle architectures developed under the Metis TechBio and Eli Lilly collaboration are intended to have potential applications across multiple disease areas.
• ▪Metis TechBio and Eli Lilly aim to discover and optimize novel lipid nanoparticle architectures that could enhance tissue specificity and therapeutic performance.